This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Date:

November 13, 2024

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.

Source link

Phillip Lim Steps Down as Creative Director of 3.1 Phillip Lim

Nelly Furtado Says She Endured ‘Abusive Qualities' in Past Relationship

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Recent posts

Trump floats manufacturing ambassador, while his Deere tariff threat draws flak from Mark Cuban

October jobs report was a ‘head fake.’ Look at these numbers instead before Election Day.

Earnings Watch: Walmart reports this week. Its ‘resilience’ will be tested amid signs of consumer slowdown, analyst says

Trump tariffs: These states would be hit hardest by proposed import taxes

Amazon Prime Video’s ad event beat targets. That’s good news for the stock, says BofA.

Geo Group and CoreCivic move guidance in opposite directions, a day after both prison stocks soared

Here’s how economic issues could help Republicans take back the U.S. Senate

At Ross, ‘value offers’ worked, but discount retailer sounds cautious for the rest of the year

Lyft told drivers they could make more than $30 an hour. The FTC says it deceived them.

These 20 stocks have been the S&P 500’s biggest losers so far in 2024

Levi’s sales miss expectations, and jeans maker forecasts higher costs for marketing and logistics

Core & Main’s stock drops 13% as earnings and revenue fall short

Perrigo voluntarily recalls 16,500 cans of baby formula because of excessive levels of vitamin D

A U.S. ‘sovereign wealth fund’? Please, no.

Nvidia’s bonds are a buy even as the stock sputters over growth concerns

Related articles

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Powell says Fed doesn’t need to hurry to cut interest rates

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Off-price retailers could thrive, BofA says, citing this bullish data point

Republicans clinch control of House, setting stage for quicker action on extending tax cuts

Cava is riding a strong wave, but the stock’s quadrupling in 2024 has analysts wary

Wells Fargo touches all-time high as analyst hikes price target to new level

Tesla is likely to thrive in a Trump administration. These are the ways these analysts see it happening.

Company

Follow us